Meeting
2018 Gastrointestinal Cancers Symposium
Comparative effectiveness of nab-paclitaxel plus gemcitabine versus FOLFIRINOX in metastatic pancreatic cancer: A nationwide chart review in the United States.
Authors
Sunnie S. Kim
Georgetown University, Washington, DC
Sunnie S. Kim , James Signorovitch , Hongbo Yang , Oscar Patterson-Lomba , Cheryl Xiang , Brian Ung , Monika Parisi , John Marshall
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Multidisciplinary Treatment
Citation
J Clin Oncol 36, 2018 (suppl 4S; abstr 376)
DOI
10.1200/JCO.2018.36.4_suppl.376
Abstract #
376
Poster Bd #
H13
Abstract Disclosures
Similar Posters
Poster
2020 Gastrointestinal Cancers Symposium
Clinical outcomes of first-line FOLFIRINOX versus gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer at the Yale Smilow Healthcare System.
First Author: Timil Patel
Poster
2018 Gastrointestinal Cancers Symposium
Efficacy of nab-paclitaxel plus gemcitabine (AG) vs. FOLFIRINOX as first line chemotherapy for metastatic pancreatic cancer (mPC): Real world experiences.
First Author: Inhwang Hwang
Poster
2017 Gastrointestinal Cancers Symposium
Efficacy of chemotherapy in patients with recurrent pancreatic cancer.
First Author: Akihiro Ohba
Poster
2016 ASCO Annual Meeting
Comparative effectiveness of FOLFIRINOX or nab-paclitaxel plus gemcitabine in locally advanced or metastatic pancreatic cancer: A population-based analysis.
First Author: Ying Wang